Protein blocking offers new treatment possibilities for AMD

In an article published in the April issue of Nature Medicine, a team of French researchers report that inactivating or blocking the receptors of the protein Slit2 in mice inhibited the growth of faulty retinal blood vessels caused by vasoproliferative diseases such as age-related macular degeneration (AMD). Slit2 is known for its role in the development of nerve connections and is a culprit in the development of certain cancers.

Wet AMD is typically managed with regular injections of antiangiogenic drugs to inhibit the growth of abnormal blood vessels within the retina. These drugs target a specific factor called the vascular endothelial growth factor (VEGF).

New therapies targeting the Slit2 protein will offer benefits for patients suffering from AMD, especially for those who do not respond to the current treatments targeting VEGF.

Further information: http://presse-inserm.fr/en/caring-for-blindness-a-new-protein-in-sight/18933/

 

Featured Posts

Bausch + Lomb Receives Health Canada Approval of LUMIFY® Redness Reliever Eye Drops

LUMIFY® is Canada's First and Only Over-the-Counter Eye Drop with Low-Dose Brimonidine for the Relief of Eye Redness

Learn More

Lanvin Unveils New Mother and Child Sunglasses

These feminine sunglasses are designed in an oversized rectangular silhouette, crafted in lightweight acetate.

Read more

A Successful First Half Year for ZEISS

The positive trend continues at the ZEISS Group, which had a positive end to the first six months of fiscal year 2021/22 (ended 31 March 2022) that was significantly higher than the very good result seen in the previous year.

Read more

SILMO Paris 2022: Return to Normalcy

After the successful 2021 reunion, the upcoming edition heralds a return to normalcy and the much-awaited SILMO Paris.

Read more

RBC Partners with CNIB Frontier Accessibility to Improve Accessibility for Canadians

RBC has partnered with CNIB Frontier Accessibility to offer BlindSquare, the world’s most widely used accessible GPS app developed for people who are blind or partially sighted, at more than 305 RBC branches across Canada.

Read more

Bausch + Lomb Receives Health Canada Approval of LUMIFY® Redness Reliever Eye Drops

LUMIFY® is Canada's First and Only Over-the-Counter Eye Drop with Low-Dose Brimonidine for the Relief of Eye Redness

Learn More

Lanvin Unveils New Mother and Child Sunglasses

These feminine sunglasses are designed in an oversized rectangular silhouette, crafted in lightweight acetate.

Read More

A Successful First Half Year for ZEISS

The positive trend continues at the ZEISS Group, which had a positive end to the first six months of fiscal year 2021/22 (ended 31 March 2022) that was significantly higher than the very good result seen in the previous year.

Read More

SILMO Paris 2022: Return to Normalcy

After the successful 2021 reunion, the upcoming edition heralds a return to normalcy and the much-awaited SILMO Paris.

Read More

RBC Partners with CNIB Frontier Accessibility to Improve Accessibility for Canadians

RBC has partnered with CNIB Frontier Accessibility to offer BlindSquare, the world’s most widely used accessible GPS app developed for people who are blind or partially sighted, at more than 305 RBC branches across Canada.

Read More

Bausch + Lomb Receives Health Canada Approval of LUMIFY® Redness Reliever Eye Drops

LUMIFY® is Canada's First and Only Over-the-Counter Eye Drop with Low-Dose Brimonidine for the Relief of Eye Redness

Learn More

Lanvin Unveils New Mother and Child Sunglasses

These feminine sunglasses are designed in an oversized rectangular silhouette, crafted in lightweight acetate.

Read more

A Successful First Half Year for ZEISS

The positive trend continues at the ZEISS Group, which had a positive end to the first six months of fiscal year 2021/22 (ended 31 March 2022) that was significantly higher than the very good result seen in the previous year.

Read more

SILMO Paris 2022: Return to Normalcy

After the successful 2021 reunion, the upcoming edition heralds a return to normalcy and the much-awaited SILMO Paris.

Read more

RBC Partners with CNIB Frontier Accessibility to Improve Accessibility for Canadians

RBC has partnered with CNIB Frontier Accessibility to offer BlindSquare, the world’s most widely used accessible GPS app developed for people who are blind or partially sighted, at more than 305 RBC branches across Canada.

Read more

Bausch + Lomb Receives Health Canada Approval of LUMIFY® Redness Reliever Eye Drops

LUMIFY® is Canada's First and Only Over-the-Counter Eye Drop with Low-Dose Brimonidine for the Relief of Eye Redness

Learn More

Lanvin Unveils New Mother and Child Sunglasses

These feminine sunglasses are designed in an oversized rectangular silhouette, crafted in lightweight acetate.

Read more

A Successful First Half Year for ZEISS

The positive trend continues at the ZEISS Group, which had a positive end to the first six months of fiscal year 2021/22 (ended 31 March 2022) that was significantly higher than the very good result seen in the previous year.

Read more

SILMO Paris 2022: Return to Normalcy

After the successful 2021 reunion, the upcoming edition heralds a return to normalcy and the much-awaited SILMO Paris.

Read more

RBC Partners with CNIB Frontier Accessibility to Improve Accessibility for Canadians

RBC has partnered with CNIB Frontier Accessibility to offer BlindSquare, the world’s most widely used accessible GPS app developed for people who are blind or partially sighted, at more than 305 RBC branches across Canada.

Read more